HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintained a price target of $38.
October 10, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $38.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $38 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100